Non-lipid-related effects of statins

Annals of Medicine

Volumn 32, Issue 3, 2000, Pages 164-176

  Bellosta, Stefano ^a   Ferri, Nicola ^a   Bernini, Franco ^b   Paoletti, Rodolfo ^a   Corsini, Alberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Arterial smooth muscle cell proliferation; Atherosclerosis; Cancer; Cholesterol accumulation; Endothelial function; Inflammation; Macrophages; Migration; Statins; Thrombosis

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

APOPTOSIS; ARTERY MUSCLE; ATHEROSCLEROSIS; CANCER; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; HUMAN; MACROPHAGE; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0034053890     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890008998823     Document Type: Review

References (157)

1. Corsini A, Bellosta S, Baetta R, Fumagalli R, Bernini F. New insights into the pharmacodynamics and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-28.
2. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91.
3. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22.
4. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ III, Jones PH, West, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study (LCAS)). Am J Cardiol 1997; 80: 278-86.
5. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40.
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57.
7. Riegger G, Abletshauser C, Ludwig M, Schwandt P, Widimsky J, Weidinger G, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999; 144: 263-70.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
10. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
11. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341: 70-6.
12. Hunninghake DB. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1992; 3: 22-8.
13. Gotto AM Jr, Grundy SM. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data. Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, Ninth Council meeting. Circulation 1999; 99: E1-E7.
14. Feussner G. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1994; 5: 59-68.
15. Grunler J, Ericsson J, Dallner G. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim Biophys Acta 1994; 1212: 259-77.
16. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
17. Bernini F, Didoni G, Bonfadini G, Bellosta S, Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis 1993; 104: 19-26.
18. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993; 101: 117-25.
19. Glomset JA, Gelb MH, Farnsworth CC. Prenyl proteins in eukaryotic cells: a new type of membrane anchor. Trends Biochem Sci 1990; 15: 139-42.
20. Maltese WA. Post-translational modification of proteins by isoprenoids in mammalian cells. FASEB J 1990; 4: 3319-28.
21. Glomset JA, Farnsworth CC. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu Rev Cell Biol 1994; 10: 181-205.
22. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
23. Wissler RW. Update on the pathogenesis of atherosclerosis. Am J Med 1991; 91 (Suppl 1B): 1B-3S-9S.
24. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990; 15: 1667-87.
25. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941-4.
26. Burleigh MC, Briggs AD, Lendon CL, Davies MJ, Born GV, Richardson PD. Collagen types I and II, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: snap-wise variations. Atherosclerosis 1992; 96: 71-81.
27. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-8.
28. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-8.
29. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50.
30. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witzum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
31. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998; 97:1129-35.
32. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337: 408-16.
33. Bjorkerud B, Bjorkerud S. Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts. Arterioscler Thromb Vasc Biol 1996; 16: 416-24.
34. Broze GJ Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992; 29: 159-69.
35. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138: 271-80.
36. Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997; 128: 11-8.
37. Kleinveld HA, Demacker PNM, De Haan AFJ, Stalenhoef AFH. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur J Clin Invest 1993; 23: 289-95.
38. Hoffman R, Brook GJ, Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 1992; 93: 105-13.
39. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993; 1165: 335-8.
40. Wagner AH, Köhler T, Rückschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-9.
41. Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998; 31: 39-45.
42. Suzumura K, Yasuhara M, Tanaka K, Suzuki T. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem Pharmacol 1999; 57: 697-703.
43. Umetani N, Kanayaraa Y, Okamura M, Negoro N, Takeda T. Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages. Biochim Biophys Acta 1996; 1303: 199-206.
44. Hrboticky N, Draude G, Hapfelmeier G, Lorenz R, Weber PC. Lovastatin decreases the receptor-mediated degradation of acetylated and oxidized LDLs in human blood monocytes during early stage of differentiation into macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 1267-75.
45. Pietsch A, Erl W, Lorenz RL. Lovastatin reduces the expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem Pharmacol 1996; 52: 433-9.
46. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
47. Forstermann U, Mugge A, Alheid U, Haverich A, Frolich JC. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res 1988; 62: 185-90.
48. Jeserich M, Múnzel T, Just H, Drexier H. Reduced plasma L-arginine in hypercholesterolemia. Lancet 1992; 339: 561.
49. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90: 1168-72.
50. Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996; 97: 1989-94.
51. Osborne JA, Lento PH, Siegfried MR, Stahl GL, Fusman B, Lefer AM. Cardiovascular effects of acute hypercholesterolemia in rabbits. J Clin Invest 1989; 83: 465-73.
52. Eichstadt HW, Eskotter H, Hoffmann I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76: 122A-5A.
53. Guethlin M, Kasel AM, Coppenrath K, Ziegler S, Delius W, Schwaiger M. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 1999; 99: 475-81.
54. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999; 99: 2871-5.
55. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
56. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684-91.
57. Laufs U, La Fata V, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 31725-9.
58. Liao JK, Zulueta JJ, Feng-Sheng Y, Peng H, Cote CG, Hassoun PM. Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen. J Clin Invest 1995; 96: 2661-6.
59. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998; 95: 8880-5.
60. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin 1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-9.
61. Mueck AO, Seeger H, Lippert TH. Fluvastatin reduces endothelin secretion of cultured human umbilical vein endothelial cells. Eur J Clin Pharmacol 1999; 55: 625-6.
62. Roullet JB, Xue H, Pappu AS, Roullet C, Holcomb S, McCarron DA. Mevalonate availability and cardiovascular functions. Proc Natl Acad Sci U S A 1993; 90: 11728-32.
63. Roullet JB, Xue H, Roullet CM, Fletcher WS, Cipolla MJ, Harker CT, et al. Mevalonate availability affects human and rat resistance vessel function. J Clin Invest 1995; 96: 239-44.
64. Roullet JB, Xue H, Chapman J, McDougal P, Roullet CM, McCarron DA. Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J Clin Invest 1996; 97: 2384-90.
65. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993; 178: 449-60.
66. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998; 152: 353-8.
67. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990; 344: 254-7.
68. Warner SJC, Friedman GB, Libby P. Immune interferon inhibits proliferation and induces 2′-5′-oligoadenylate synthetase gene expression in human vascular smooth muscle cells. J Clin Invest 1989; 83: 1174-82.
69. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991; 11: 1223-30.
70. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997; 349: 1391-2.
71. Neumann FJ, Marx N, Gawaz M, Brand K, Ott I, Rokitta C, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997; 95: 2387-94.
72. Green F, Humphries S. Control of plasma fibrinogen levels. Baillières Clin Haematol 1989; 2: 945-59.
73. Shiomi M, Ito T, Tsukada T, Yata T, Watanabe Y, Tsujita Y, et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 1938-44.
74. Shiomi M, Ito T. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol 1999; 126: 961-8.
75. Padgett RC, Heistad DD, Mugge A, Armstrong ML, Piegors DJ, Lopez JAG. Vascular responses to activated leukocytes after regression of atherosclerosis. Circ Res 1992; 70: 423-9.
76. Weber C, Erl W, Weber KSC, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212-7.
77. Bustos C, Hernandez-Presa H, Ortego M, Tunon J, Ortega L, Perez F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057-64.
78. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 1997; 17: 1521-6.
79. Duzendorfer S, Rothbucher D, Schratzberger P, Reinisch N, Kahler CM, Wiedermann CJ. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 1997; 81: 963-9.
80. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996; 18: 669-75.
81. Ikeda U, Shimada K. Statins and monocytes. Lancet 1999; 353: 2070.
82. Bernini F, Scurati N, Bonfadini G, Fumagalli R. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages. Arterioscl Thromb Vasc Biol 1995; 15: 1352-8.
83. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137 Suppl: S101-9.
84. Corsini A, Arnaboldi L, Raiteri M, Quarato P, Faggiotto A, Paoletti R, et al. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol Res 1996; 33: 56-62.
85. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R. Pathogenesis of atherosclerosis and the role of drug intervention: focus on HMG-CoA reductase inhibitors. Am J Cardiol 1995; 76: 21A-8A.
86. Raiteri M, Arnaboldi L, McGeady P, Gelb MH, Verri D, Tagliabue C, et al. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther 1997; 281: 1144-53.
87. Scott W. Hydrophilicity and the differential pharmacology of pravastatin. In: Wood C, ed. Lipid management: pravastatin and the differential pharmacology of HMG-CoA reductase inhibitors. London Round Table Series no 16. London, UK: Royal Society of Medicine Service; 1989: 17-25.
88. Komai T, Shigehara E, Tokui T, Koga T, Ishigami M, Kuroiwa C, et al. Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 1992; 43: 667-70.
89. Bandoh T, Mitani H, Niihashi M, Bandoh T, Mitani H, Niihashi M, et al. Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. Eur J Pharmacol 1996; 315: 37-42.
90. Igarashi M, Takeda Y, Mori S, Ishibashi N, Komatsu E, Takahashi K, et al. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYW6228 and its inhibitory effect on vascular smooth muscle cell growth. Br J Pharmacol 1997; 120: 1172-8.
91. Soma MR, Donetti E, Parolini C, Mazzini G, Ferrari C, Fumagalli R, et al. HMG-CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1993; 13: 571-8.
92. Soma MR, Parolini C, Donetti E, Fumagalli R, Paoletti R. Inhibition of isoprenoids biosynthesis and arterial smooth muscle cell proliferation. J Cardiovasc Pharmacol 1995; 25: S20-4.
93. Bocan TMA, Mazur MJ, Mueller SB, Brown EQ, Sliskovic DR, O'Brien PM, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis 1994; 111: 127-42.
94. Gellman J, Ezekowitz MD, Sarembock IJ, Azrin MA, Nochomowitz LE, Lerner E, et al. Effect of lovastatin on intimal hyperplasia after balloon angioplasty. A study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991; 17: 251-9.
95. Zhu BQ, Sievers RE, Sun YP, Isenberg WM, Parmley WW. Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J Cardiovasc Pharmacol 1992; 19: 246-55.
96. Dain JG, Fu E, Gorski J, Nicoletti J, Scallen TJ. Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos 1993; 21: 567-72.
97. Tse FLS, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses of normal volunteers. J Clin Pharmacol 1992; 32: 630-8.
98. Corsini A, Pazzucconi F, Pfister P, Paoletti R, Sirtori CR. Inhibitor of proliferation of arterial smooth muscle cells by fluvastatin. Lancet 1996; 348: 1584.
99. Bochaton Piallant ML, Gabbiani F, Redard M, Desmoulière A, Gabbiani G. Apoptosis participates in cellularity regulation during rat aortic intimai thickening. Am J Pathol 1995; 146: 1059-64.
100. Han DKM, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G. Evidence for apoptosis in human atherogenesis and in rat vascular injury model. Am J Pathol 1995; 147: 267-77.
101. Isner JM, Kearney M, Boartman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation 1995; 91: 2703-11.
102. Kockx MM, Cambier BA, Bortier HE, De Meyer GR, Declercq SC, Van Cauwelaert PA, et al. Foam cell replication and smooth muscle cell apoptosis in human saphenous vein grafts. Histopathology 1994; 25: 365-71.
103. Soma MR, Baetta R, De Renzis S, Mazzini G, Davegna C, Magrassi L, et al. In vitro and in vivo enhanced anti-tumor activity of carmustine (BCNU) by simvastatin, a hypocholesterolemic drug. Cancer Res 1995; 55: 597-602.
104. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83: 490-500.
105. Baetta R, Donetti E, Comparato C, Calore M, Rossi A, Teruzzi C, et al. In vitro and in vivo apoptosis by atorvastatin in stimulated smooth muscle cells. Pharmacol Res 1997; 36: 115-21.
106. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty, final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999; 20: 58-69.
107. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB III, Ivanhoe R, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994; 331: 1331-7.
108. Bertrand ME, McFadden EP, Fruchart JC, van Belle E, Commeau P, Grollier G, et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1997; 30: 863-9.
109. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
110. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-81.
111. Fernandez-Ortiz A, Badimon J, Falk E, Fuster V, Meyer B, Mailhac A, et al. Characterization of the relative thrombo-genicity of atherosclerotic plaque components: implications for consequences of plaque rupture. Am J Coll Cardiol 1994; 23: 1562-9.
112. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941-4.
113. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-8.
114. 2+ and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin. Arterioscler Thromb Vasc Biol 1995; 15: 759-64.
115. Osamah H, Mira R, Sorina S, Shlomo K, Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 1997; 44: 77-83.
116. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
117. Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33: 1294-304.
118. Szczeklik A, Musial J, Undas A, Gajewski P, Gora P, Swadzba J, et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999; 33: 1286-93.
119. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Circ Res 1998; 83: 683-90.
120. Essig M, Vrtovsnik F, Nguyen G, Sraer JD, Friedlander G. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol 1998; 9: 1377-1388.
121. Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
122. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 1989; 86: 2839-43
123. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 265-72.
124. Koppensteiner R, Minar E, Ehringer H. Effect of lovastatin on hemorheology in type II hyperlipoproteinemia. Atherosclerosis 1990; 83: 53-8.
125. Beigel Y, Fuchs J, Snir M, Green P, Kurie Y, Djaldetti M. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol 1991; 31: 512-7.
126. Siperstein MD, Gyde AM, Morris HP. Loss of feedback control of hydroxymethylglutaryl coenzyme A reductase in hepatomas. Proc Natl Acad Sci U S A 1971; 68: 315-7.
127. Kandutsch AA, Hancock RL. Regulation of the rate of sterol synthesis and the level of β-hydroxy-β-methylglutaryl coenzyme A reductase activity in mouse liver and hepatomas. Cancer Res 1971; 31: 1396-401.
128. Maltese WA. 3-Hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors. Neurology 1983; 33: 1294-9.
129. Dunnington DJ, Prichett W, Greig R. Stimulation of anchorage independent proliferation of human adrenocortical carcinoma cells by inhibition of cholesterol biosynthesis. Biochem Biophys Res Commun 1989; 165: 219-25.
130. Bennis F, Favre G, Le Gaillard F, Soula G. Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int J Cancer 1993; 55: 640-5.
131. Maltese WA. Induction of differentiation in murine neuroblastoma cells by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Biochim Biophys Res Commun 1984; 120: 454-60.
132. Soma MR, Pagliarini P, Butti G, Paoletti R, Paoletti P, Fumagalli R. Simvastatin, an inhibitor of cholesterol biosynthesis, shows synergistic effect with N,N′-Bis (2-chloroethyl)-N-nitrosourea and β-interferon on human glioma cells. Cancer Res 1992; 52: 4348-5355.
133. Newman A, Clutterbuck RD, Powles RL, Catovsky D, Millar JL. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma 1997; 24: 533-7.
134. Kiluchi T, Nagata Y, Abe T. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells. J Neurooncol 1997; 34: 233-9.
135. Choi JW, Jung SE. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells. J Pharmacol Exp Ther 1999; 289: 572-9.
136. Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest 1985; 76: 1748-54.
137. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: ras research yields a potential cancer Therapeutic. Cell 1994; 77: 175-8.
138. Soma MR, Baetta R, De Renzis R, Mazzini G, Davegna C, Magrassi L, et al. In vivo enhanced antitumor activity of carmustine [N,N′-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. Cancer Res 1995; 55: 597-602.
139. Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem 1996; 66: 710-6.
140. Jones KJ, Couldwell WT, Hinton DR, Su Y, He S, Anker L, et al. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 1994; 205: 1681-7.
141. Perez-Sala D, Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 1994; 199: 1209-15.
142. Perez-Sala D, Collado-Escobar D, Mollinedo F. Intracellular alkalination suppresses lovastatin-induced apoptosis in HL60 cells through the inactivation of a pH-dependent indonuclease. J Biol Chem 1995; 270: 6235-42.
143. Baetta R, Paoletti R, Fumagalli R, Soma MR. Mevalonate modulation of cell proliferation and apoptosis. Oncol Rep 1997; 4: 257-61.
144. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2: 483-91.
145. Lamer J, Jane J, Laws E, Packer R, Myers C, Shaffrey M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 1998; 21: 579-83.
146. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999; 96: 133-8.
147. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-9.
148. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992; 33: 1569-82.
149. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 1992; 41: 229-35.
150. La Ville A, Moshy R, Turner PR, Miller NE, Lewis B. Inhibition of cholesterol synthesis reduces low-density-lipoprotein apoprotein B production without decreasing very-low-density-lipoprotein apoprotein B synthesis in rabbits. Biochem J 1984; 218: 321-3.
151. Corsini A, Bernini F, Quarato P, Donetti E, Bellosta S, Fumagalli R, et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996; 87: 458-68.
152. Sakai M, Kobori S, Matsumura T, Biwa T, Sato Y, Takemura T, et al. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis 1997; 133: 51-9.
153. Cignarella A, Brennhausen B, von Eckardstein A, Assmann G, Cullen P. Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1322-9.
154. Masaaki K, Kurose I, Russell J, Granger DN. Effect of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscl Thromb Vasc Biol 1997; 17: 1521-6.
155. Kaesemeyer WH. Pravastatin sodium activates endothelial nitric oxide synthase independently of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234-41.
156. 2+ channels in rat islet β-cells. Br J Pharmacol 1999; 126: 1205-13.
157. 2+ mobilization in vascular smooth muscle cells. J Cardiovasc Pharmacol 1996; 27: 383-91.